uniQure (NASDAQ:QURE) Given Overweight Rating at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of uniQure (NASDAQ:QURE) in a research report released on Wednesday morning,Benzinga reports. The firm currently has a $28.00 target price on the biotechnology company’s stock.

A number of other research firms have also issued reports on QURE. The Goldman Sachs Group increased their target price on shares of uniQure from $6.00 to $10.00 and gave the stock a “neutral” rating in a report on Friday, August 2nd. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of uniQure in a research report on Tuesday, August 20th. Raymond James reissued an “outperform” rating and issued a $20.00 price objective on shares of uniQure in a research report on Thursday, October 10th. Finally, StockNews.com raised shares of uniQure to a “sell” rating in a research report on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $17.00.

uniQure Stock Performance

Shares of QURE stock opened at $7.79 on Wednesday. The firm’s 50 day moving average price is $5.77 and its 200-day moving average price is $5.83. The company has a debt-to-equity ratio of 0.92, a quick ratio of 7.36 and a current ratio of 6.51. uniQure has a one year low of $3.73 and a one year high of $11.35. The firm has a market cap of $379.71 million, a P/E ratio of -1.57 and a beta of 0.90.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($1.12) by $0.21. The firm had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. As a group, equities research analysts predict that uniQure will post -4.1 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. abrdn plc increased its stake in uniQure by 381.7% in the third quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock valued at $9,510,000 after purchasing an additional 1,528,581 shares during the period. Vanguard Group Inc. boosted its holdings in shares of uniQure by 11.4% in the first quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock valued at $5,577,000 after acquiring an additional 109,740 shares in the last quarter. Privium Fund Management B.V. boosted its holdings in shares of uniQure by 16.3% in the third quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock valued at $3,672,000 after acquiring an additional 104,500 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of uniQure by 4.3% in the first quarter. BNP Paribas Financial Markets now owns 736,724 shares of the biotechnology company’s stock valued at $3,831,000 after acquiring an additional 30,054 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its holdings in shares of uniQure by 133.1% in the first quarter. Acadian Asset Management LLC now owns 613,490 shares of the biotechnology company’s stock valued at $3,189,000 after acquiring an additional 350,291 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.